CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Rhea-AI Summary
Quoin Pharmaceuticals (NASDAQ: QNRX) provided a clinical and regulatory update for its QRX009 topical rapamycin programs on April 28, 2026. The company plans multiple investigator-led studies: a Pachyonychia Congenita (PC) trial led by Professor Edel O’Toole, plus Gorlin Syndrome (GS) and Tuberous Sclerosis Complex (TSC) studies.
Quoin reported achieving target loading concentrations of 4% and 5% for its lotion and dermal patch, and is targeting an IND submission to the FDA in Q3 2026 for an additional indication. The company expects potential active testing in up to four indications before end of 2026 and is also advancing QRX003 toward pivotal trials for Netherton Syndrome.
AI-generated analysis. Not financial advice.
Positive
- Investigator-led PC trial to be led by Professor Edel O’Toole
- IND submission targeted Q3 2026 for an additional QRX009 indication
- Achieved 4% and 5% loading concentrations for lotion and dermal patch
- Potential for active testing in four indications before end of 2026
Negative
- None.
News Market Reaction – QNRX
On the day this news was published, QNRX declined 0.18%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $20K from the company's valuation, bringing the market cap to $10.91M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
QNRX was down 4.21% pre-news while peers showed mixed moves: AZTR -2.65%, XRTX +3.12%, CNSP -5.76%, JAGX -26.92%, XBIO -6.48%. Momentum scanner flagged ONCO up 5.92% and XRTX down 7.68%, reinforcing a stock-specific rather than uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Earnings and financing | Neutral | -18.4% | Full-year 2025 results, private placement up to $104.5M, cash runway into 2027. |
| Mar 25 | FDA meeting update | Positive | +15.9% | Constructive FDA Type C meeting; single Phase 3 may support approval. |
| Mar 19 | Earnings date notice | Neutral | +5.4% | Announcement of timing for Q4 and full-year 2025 results and update. |
| Mar 11 | Fast Track designation | Positive | -1.1% | FDA Fast Track for QRX003 for Netherton Syndrome, a rare severe disease. |
| Feb 26 | Awareness campaign | Positive | +0.1% | NETHERTON NOW awareness campaign milestones and late-stage QRX003 positioning. |
Recent history shows mixed reactions: positive regulatory and clinical updates sometimes coincided with gains, but funding and Fast Track news also saw negative or flat moves, indicating inconsistent pricing of ostensibly positive milestones.
Over recent months, Quoin reported several key milestones. On Mar 26, 2026, Q4 and 2025 results plus a private placement of up to $104.5M and year-end cash of $18.7M were followed by a -18.39% move. A constructive FDA Type C meeting on Mar 25 drove a +15.88% reaction. Fast Track designation for QRX003 on Mar 11 saw a slight decline, while Rare Disease Day awareness efforts and the earnings-date announcement produced modest positive moves. Today’s QRX009 update extends this pattern of frequent clinical and regulatory news in rare dermatologic indications.
Regulatory & Risk Context
An effective Form S-3 registers the resale of up to 10,045,455 ADSs by selling shareholders. Quoin will not receive proceeds from these resales but could receive up to $88.7 million if accompanying warrants are exercised for cash, with the filing itself highlighting substantial potential dilution relative to prior ADS outstanding levels.
Market Pulse Summary
This announcement details a multi-pronged QRX009 strategy with investigator-led trials in Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, plus planned IND filings in Q3 2026. It complements ongoing pivotal work on QRX003 for Netherton Syndrome and a Peeling Skin Syndrome program. Historically, Quoin has paired clinical progress with significant financings and registered resales of up to 10,045,455 ADSs and potential warrant proceeds of $88.7 million. Investors may watch execution on trial initiations and regulatory timelines across these rare dermatologic indications.
Key Terms
topical rapamycin medical
pachyonychia congenita medical
gorlin syndrome medical
tuberous sclerosis complex medical
investigational new drug application regulatory
orphan diseases medical
netherton syndrome medical
AI-generated analysis. Not financial advice.
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications.
Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita
Study Will be Led By Professor Edel O’Toole, Queen Mary University of London, Globally Recognized Leader in Pachyonychia Congenita
Quoin Also Planning to Initiate Investigator Led Studies in Gorlin Syndrome and Tuberous Sclerosis Complex
In addition to the Investigator Led Studies Company is Targeting to File Investigational New Drug Application to US Food and Drug Administration for QRX009 for an additional indication in Q3 2026
Quoin has Established Relationships With Key Advocacy Foundations including The PC Project and The Gorlin Syndrome Alliance as well as with Leading KOLs and Clinicians
ASHBURN, Va., April 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today provided a clinical and regulatory update for its QRX009 topical rapamycin development programs. The Company is planning to initiate several investigator-led clinical studies for its QRX009 topical rapamycin lotion in a number of key target indications. The first study will be in, Pachyonychia Congenita (PC), a rare skin disease with no approved treatments or cure. This study will be led by Professor Edel O’Toole of Queen Mary University of London, a globally recognized clinician and thought-leader in PC who has previous experience in clinical trials for PC. Quoin believes that Professor O’Toole’s expertise coupled with the Company’s proprietary delivery technology could lead to improved clinical outcomes for PC patients over past studies. The Company is targeting initiating this study in Q3 of this year. In addition, Quoin is planning to initiate investigator-led clinical studies in both Gorlin Syndrome (GS) and Tuberous Sclerosis Complex (TSC) later this year. Finally, Quoin is on track to submit an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for QRX009 for an additional indication in Q3 of this year.
Dr. Michael Myers, Chief Executive Officer of Quoin commented, “We are very pleased to provide this important update for our QRX009 topical rapamycin programs. Since we announced that we had achieved our target loading concentrations of
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009 that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, PC, GS, TSC, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to plans to initiate several investigator-led clinical studies for its QRX009 topical rapamycin lotion in a number of key target indications; the Company initiating investigator-led study in Pachyonychia Congenita; Professor O’Toole’s expertise coupled with the Company’s proprietary delivery technology leading to improved clinical outcomes for PC patients over past studies; initiating the study for QRX009 in Q3 of this year; plans to initiate investigator-led clinical studies in GS and TSC later this year; being on track to submit an IND to the FDA for QRX009 in Q3 of this year; working diligently to advance the Company’s products into the clinic; the potential for QRX009 to be in active testing in four separate clinical indications before the end of 2026; targeting an IND application for Peeling Skin Syndrome in Q2 2026; targeting rare skin diseases for which there are no or limited approved treatments; 2026 shaping up to be a transformational year for the Company as it advances to pivotal trials for QRX003 for the treatment of NS and moves forward across multiple fronts; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, PC, GS, TSC, microcystic lymphatic malformations, venous malformations, angiofibromas and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
